Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 97.03 USD -0.48% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Axsome Therapeutics Inc?
Write Note

Axsome Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Axsome Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Axsome Therapeutics Inc
NASDAQ:AXSM
Cash from Operating Activities
-$132.6m
CAGR 3-Years
-10%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$25.1B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$15B
CAGR 3-Years
-1%
CAGR 5-Years
12%
CAGR 10-Years
14%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$8B
CAGR 3-Years
-37%
CAGR 5-Years
-10%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$18.3B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$6B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
2%
No Stocks Found

Axsome Therapeutics Inc
Glance View

Market Cap
4.7B USD
Industry
Pharmaceuticals

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 108 full-time employees. The company went IPO on 2015-11-19. The firm is engaged in developing therapies for the management of central nervous system (CNS) disorders. The firm's core CNS portfolio includes four CNS product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral, rapidly absorbed and multi-mechanistic investigational medicine under development for the acute treatment of migraine. AXS-07 consists of Molecular Solubility Enhanced Inclusion Complex (MoSEIC), meloxicam and rizatriptan. AXS-12, reboxetine, is an oral, investigational medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine, is an oral, investigational medicine in development for the treatment of fibromyalgia.

AXSM Intrinsic Value
104.33 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Axsome Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-132.6m USD

Based on the financial report for Sep 30, 2024, Axsome Therapeutics Inc's Cash from Operating Activities amounts to -132.6m USD.

What is Axsome Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-28%

Over the last year, the Cash from Operating Activities growth was 7%. The average annual Cash from Operating Activities growth rates for Axsome Therapeutics Inc have been -10% over the past three years , -28% over the past five years .

Back to Top